Clinical Trial Update: Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study of acalabrutinib (ACP-196), a BTK inhibitor, in de novo activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma Activated B-cell Type

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL) | Phase 1 | Status: COMPLETED | Results posted: 2020-07-29